Project Oncology®

NUT carcinoma is a rare, aggressive form of cancer that’s highly resistant to therapy and has no defined standard treatment. Joining Dr. Jacob Sands to discuss the best diagnostic and treatment strategies for NUT carcinoma is Dr. Jia Luo, medical oncologist at Dana-Farber Cancer Institute and an Instructor of Medicine at Harvard Medical School in Boston.

Subcutaneous cancer immunotherapies may offer a faster, more resource-efficient alternative to intravenous administration, improving patient convenience and accessibility while maintaining efficacy. However, careful monitoring for immunotherapy-related toxicities remains essential. Joining Dr. Charles Turck to discuss these key considerations for subcutaneous cancer immunotherapies is Dr. Matthew Hadfield, Assistant Professor of Medicine at Brown University/Alpert School of Medicine.

Despite advances in the treatment of HR-positive HER2-negative advanced breast cancer, patients with PIK3CA-mutated disease who progress after a CDK4/6 inhibitor still face limited effective and tolerable treatment options.1 This unmet need has fueled interest in zovegalisib (formerly RLY-2608), a next generation, pan-mutant-selective PI3Kα inhibitor designed to spare wild-type protein and potentially reduce class-related toxicities.2 Dr. Sarah Sammons joins Dr. Charles Turck to review key findings from the first-in-human ReDiscover trial of zovegalisib + fulvestrant that supported initiation of the Phase 3 ReDiscover-2 study3,4, which is currently enrolling. They also discuss ReDiscover-2 eligibility criteria, along with patient selection and screening considerations, using hypothetical case scenarios. Dr. Sammons is the Associate Director of the Metastatic Breast Cancer Program at the Dana-Farber Cancer Institute in Boston, Massachusetts.

References:

1. Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021;22(7)doi:10.3390/ijms22073464
2. Varkaris A, Pazolli E, Gunaydin H, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Kα inhibitor that decouples antitumor activity from hyperinsulinemia. Cancer Discovery. 2024;14(2):240–257. doi:10.1158/2159-8290.cd-23-0944
3. ClinicalTrials.gov. NCT06982521. Accessed April 12, 2026. https://clinicaltrials.gov/study/NCT06982521
4. Rugo HS, Saura C, Jhaveri K, et al. Poster PS5-08-25: …

This is a non-certified educational series produced and controlled by ReachMD.

Timely referral for CAR T-cell therapy remains a critical challenge for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). From communication gaps between providers to logistical challenges and delays, barriers throughout the treatment pathway can limit timely access to care. Tune in to learn about evolving strategies that can help us streamline coordination and expand access to CAR T-cell therapy as Dr. Steve Jackson speaks with Dr. Matthew Matasar and Dr. Tycel Phillips. Dr. Matasar is the Chief of Blood Disorders at Rutgers Cancer Institute and a Professor of Medicine at Rutgers Robert Wood Johnson Medical School in New Brunswick, New Jersey. Dr. Phillips is an Associate Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope in Duarte, California.

Could emerging biomarkers redefine how we assess response and recurrence risk in muscle-invasive bladder cancer? To find out, Dr. Charles Turck speaks with Dr. Petros Grivas about the key findings from the phase 3 NIAGARA trial. Together, they explore how perioperative durvalumab impacts circulating tumor DNA (ctDNA) clearance and clinical outcomes, including event-free and overall survival. Their conversation also highlights the prognostic value of ctDNA and the potential for urinary tumor DNA to more closely correlate with pathologic complete response. Dr. Grivas is a Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine, as well as the Clinical Research Division at the Fred Hutchinson Cancer Center, where he's also the Medical Director of the International Program and of local and regional outreach.

Several new screening tests have been developed to help doctors find colorectal cancer early when it's most treatable and can reduce the burden of this disease and the death toll nationwide.

Host Dr. Matt Birnholz chats with Dr. John Kisiel, gastroenterologist and Assistant Professor of Medicine at Mayo Clinic College of Medicine, about new screening guidelines for detecting colorectal cancer.

From oncologists to primary care, physicians are witnessing an alarming trend in younger patients: the rising risk of colorectal cancer. To investigate this growing threat, Dr. John Russell speaks with Dr. Rich Wender, Chief Cancer Control Officer at the American Cancer Society. Dr. Wender discusses the new colorectal cancer screening guidelines set forth and the methods behind the conclusion. While comparing past guidelines, Dr. Wender considers changes in our society and environment that may be contributing to increased cancer risks in younger generations.

For more information and to review the new guidelines, go to cancer.org

Widespread health disparities have led to challenges in colorectal cancer screening. What's causing these disparities—and what are some ways we can overcome these obstacles? To dive into this topic, Dr. Jacob Sands is joined by Dr. Edith Mitchell from Thomas Jefferson University to discuss these disparities and how they may be impacting clinical outcomes.

What if molecular relapse in muscle-invasive bladder cancer (MIBC) could be detected early enough to better inform treatment decisions? To find out, Dr. Charles Turck speaks with Dr. Guru Sonpavde to explore new IMvigor011 findings presented at the 2026 ASCO Genitourinary Cancers Symposium. Their discussion highlights how ctDNA monitoring identifies early recurrence risk, captures real-time immunotherapy activity, and positions ctDNA clearance as a powerful prognostic marker. Dr. Sonpavde is the Medical Director of Genitourinary Oncology and the Phase I Clinical Research Unit, and the Christopher K. Glanz Chair for Bladder Cancer Research at the AdventHealth Cancer Institute in Orlando.

Emerging evidence is redefining bladder preservation strategies in muscle-invasive bladder cancer, with circulating tumor DNA (ctDNA) offering a novel approach to response-adapted care. Joining Dr. Charles Turck to review findings from the phase II RETAIN trials, which highlight how ctDNA clearance correlates with improved metastasis-free survival and informs risk stratification, is Dr. Pooja Ghatalia. She also examines the strengths and limitations of ctDNA, including its prognostic value for systemic recurrence and its inability to reliably detect localized disease. Dr. Ghatalia is an Associate Professor in the Department of Hematology and Oncology at Fox Chase Cancer Center at Temple University Hospital in Philadelphia, and she presented this research at the 2026 ASCO Genitourinary Cancers Symposium.